Vincent Fougner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent Fougner has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hans Skovgaard Poulsen
The DCCC Brain Tumor Center, Rigshospitalet , Copenhagen
4 shared publications - Benedikte Hasselbalch
The DCCC Brain Tumor Center, Rigshospitalet , Copenhagen
3 shared publications - Christina Westmose. Yde
Center for Genomic Medicine, Rigshospitalet , Copenhagen
3 shared publications - Thomas Urup
The DCCC Brain Tumor Center, Rigshospitalet , Copenhagen
3 shared publications - Ulrik Lassen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 shared publications Benedikte Hasselbalch
Department of Oncology, Copenhagen University Hospital, Rigshospitalet , Copenhagen
2 shared publications
Latest Publications
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf092
Identifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy
Background: Infiltrative growth is a hallmark of glioblastoma (GBM) and is a major factor in therapeutic failure. Distant progression is a surrogate marker for infiltrative growth and genetic variants predictive of distant progression may serve as novel treatment targets. The aim was to identify clinical, molecular, radiographic, and genetic factors associated with distant progression in GBM patients. Methods: From our prospective database, all consecutive GBM IDH wild type patients receiving standard therapy (Stupp regimen) from 2016 to 2021 at Rigshospitalet (Denmark) were included. Distant progression was defined as a new contrast-enhancing lesion > 2 cm from the initial lesion. Clinical, molecular, radiographic, and genomic covariates were assessed for association with time to distant progression using Cox analysis. Results: This single-center study included 353 patients, of whom 303 patients had radiographic progression. Distant progression was found in 66 patients (22%) and was associated with poor post-progression survival (P < .001). Unmethylated MGMT (hazard ratio [HR]: 2.54, 95% confidence interval [CI]: 1.62–3.97, P < .001), and multicentric disease at diagnosis (HR: 2.32, 95% CI: 1.28–4.20, P = .005) were associated with a shorter time to distant progression. In patients with a genomic tumor profile (n = 204), the NF1 gene alteration was identified as an independent predictor of distant progression (HR: 3.48, 95% CI: 1.48–8.21, P = .004) and poor survival. Conclusion: Distant progression is an aggressive progression pattern associated with a poor prognosis. Unmethylated MGMT, multicentric disease, and NF1 alteration independently predict distant progression. NF1 alteration may serve as a predictive biomarker for targeted treatment.
- 6 January 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf092
Open AccessIdentifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy
Background: Infiltrative growth is a hallmark of glioblastoma (GBM) and is a major factor in therapeutic failure. Distant progression is a surrogate marker for infiltrative growth and genetic variants predictive of distant progression may serve as novel treatment targets. The aim was to identify clinical, molecular, radiographic, and genetic factors associated with distant progression in GBM patients. Methods: From our prospective database, all consecutive GBM IDH wild type patients receiving standard therapy (Stupp regimen) from 2016 to 2021 at Rigshospitalet (Denmark) were included. Distant progression was defined as a new contrast-enhancing lesion > 2 cm from the initial lesion. Clinical, molecular, radiographic, and genomic covariates were assessed for association with time to distant progression using Cox analysis. Results: This single-center study included 353 patients, of whom 303 patients had radiographic progression. Distant progression was found in 66 patients (22%) and was associated with poor post-progression survival (P < .001). Unmethylated MGMT (hazard ratio [HR]: 2.54, 95% confidence interval [CI]: 1.62–3.97, P < .001), and multicentric disease at diagnosis (HR: 2.32, 95% CI: 1.28–4.20, P = .005) were associated with a shorter time to distant progression. In patients with a genomic tumor profile (n = 204), the NF1 gene alteration was identified as an independent predictor of distant progression (HR: 3.48, 95% CI: 1.48–8.21, P = .004) and poor survival. Conclusion: Distant progression is an aggressive progression pattern associated with a poor prognosis. Unmethylated MGMT, multicentric disease, and NF1 alteration independently predict distant progression. NF1 alteration may serve as a predictive biomarker for targeted treatment.
- Open Access
- 24 September 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (1) , 34-44
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Background: In 2016, genomic profiling was implemented for patients with grade 4 primary brain tumors at Rigshospitalet, Denmark. The aim of this study was to discover actionable alterations and to match these with targeted therapies. Methods: Between January 2016 and December 2023, 483 brain tumor patients were profiled. We retrieved clinical data and molecular data. Whole exome, whole genome, or panel sequencing, along with SNP array analyses, and RNA-seq were performed on resected primary tumor tissue. Alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT) following the European Association of Neuro-Oncology (EANO) guideline on rational molecular testing. Results: A total of 200 (41.4%) patients’ tumors harbored an alteration of interest according to the EANO guideline. Twenty (4.1%) patients had an ESCAT high-tier alteration (tier I or II), while 155 patients (32.1%) had an alteration corresponding to ESCAT IIIA. Thirty-five patients (7.2%) had an actionable alteration, and 15 (3.1%) received targeted therapy. The treated targets were BRAFV600E mutations, FGFR alterations, NTRK fusions, PDGFRA fusions, PTPRZ1-MET fusions, and TMB-high. The overall response rate was 20%, with a median duration of response of 12 months, and 47% achieved stable disease as the best response. Conclusions: Genomic profiling uncovers alterations of interest in a substantial number of patients, but only a minority are considered by the Danish National Molecular Tumor Board to have actionable alterations, and even fewer receive targeted therapy. Nevertheless, factors, such as promising targets and the increasing availability of trials, may contribute to a future increase in the number of patients benefiting from targeted therapies based on genomic profiling.
- 24 September 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 12 (1) , 34-44
Open AccessActionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Background: In 2016, genomic profiling was implemented for patients with grade 4 primary brain tumors at Rigshospitalet, Denmark. The aim of this study was to discover actionable alterations and to match these with targeted therapies. Methods: Between January 2016 and December 2023, 483 brain tumor patients were profiled. We retrieved clinical data and molecular data. Whole exome, whole genome, or panel sequencing, along with SNP array analyses, and RNA-seq were performed on resected primary tumor tissue. Alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT) following the European Association of Neuro-Oncology (EANO) guideline on rational molecular testing. Results: A total of 200 (41.4%) patients’ tumors harbored an alteration of interest according to the EANO guideline. Twenty (4.1%) patients had an ESCAT high-tier alteration (tier I or II), while 155 patients (32.1%) had an alteration corresponding to ESCAT IIIA. Thirty-five patients (7.2%) had an actionable alteration, and 15 (3.1%) received targeted therapy. The treated targets were BRAFV600E mutations, FGFR alterations, NTRK fusions, PDGFRA fusions, PTPRZ1-MET fusions, and TMB-high. The overall response rate was 20%, with a median duration of response of 12 months, and 47% achieved stable disease as the best response. Conclusions: Genomic profiling uncovers alterations of interest in a substantial number of patients, but only a minority are considered by the Danish National Molecular Tumor Board to have actionable alterations, and even fewer receive targeted therapy. Nevertheless, factors, such as promising targets and the increasing availability of trials, may contribute to a future increase in the number of patients benefiting from targeted therapies based on genomic profiling.
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , v81
CTNI-32. IMPLEMENTING GENOMIC PROFILING AS STANDARD-OF-CARE FOR GLIOBLASTOMA PATIENTS
BACKGROUND: The introduction of targeted therapies (TT) has provided few new options for glioblastoma patients (pts). Implementing genomic profiling as standard-of-care may aid in finding new treatments for glioblastoma pts. Here, we report the impact of genomic profiling in pts with WHO grade 4 CNS tumors at the Department of Oncology, Rigshospitalet, Denmark. METHODS: Eligible pts were ≥18 years of age, with newly diagnosed glioblastoma; astrocytoma, IDH mutated grade IV or diffuse midline glioma between January 2016 and December 2022. Whole exome sequencing (WES), whole genome sequencing (WGS) or panel sequencing with Trusight Oncology (TSO500) along with SNP-array analyses and RNAseq was performed on DNA/RNA extracted from tumor tissue. Tumor tissue from patients enrolled before 2021 were analyzed by WES, and from January 2021 and forth, WGS was used for frozen tissue and TSO500 for paraffin-embedded tissue. Each genomic profile was presented at a weekly national molecular tumor board meeting for multidisciplinary evaluation, treatment recommendations and matching with clinical trials. RESULTS: 387 pts had tissue samples available for analysis. Tissue from 202 patients (52%) were analyzed using WES, 174 (45%) using WGS, and 11 (3%) using TSO500. As of May 2023, of the 343 sequenced pts that have progressed after standard therapy, 14 patients (4%) have been treated with molecularly matched TTs. The actionable targets were TMB-high ( >10mut/MB) (n = 4), FGFR-mutations/-fusions (n = 4), BRAFv600E (n = 2), NTRK-fusions (n = 2), PDGFRA-fusion (n = 1) and MET-mutation (n = 1). Additionally, germline mutations were reported in 8 patients (2%). CONCLUSION: Genomic profiling revealed actionable targets and new therapeutic options for glioblastoma pts. A full and updated overview of patient characteristics, actionable targets and survival data will be presented at the meeting.
- 1 November 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , v81
Open AccessCTNI-32. IMPLEMENTING GENOMIC PROFILING AS STANDARD-OF-CARE FOR GLIOBLASTOMA PATIENTS
BACKGROUND: The introduction of targeted therapies (TT) has provided few new options for glioblastoma patients (pts). Implementing genomic profiling as standard-of-care may aid in finding new treatments for glioblastoma pts. Here, we report the impact of genomic profiling in pts with WHO grade 4 CNS tumors at the Department of Oncology, Rigshospitalet, Denmark. METHODS: Eligible pts were ≥18 years of age, with newly diagnosed glioblastoma; astrocytoma, IDH mutated grade IV or diffuse midline glioma between January 2016 and December 2022. Whole exome sequencing (WES), whole genome sequencing (WGS) or panel sequencing with Trusight Oncology (TSO500) along with SNP-array analyses and RNAseq was performed on DNA/RNA extracted from tumor tissue. Tumor tissue from patients enrolled before 2021 were analyzed by WES, and from January 2021 and forth, WGS was used for frozen tissue and TSO500 for paraffin-embedded tissue. Each genomic profile was presented at a weekly national molecular tumor board meeting for multidisciplinary evaluation, treatment recommendations and matching with clinical trials. RESULTS: 387 pts had tissue samples available for analysis. Tissue from 202 patients (52%) were analyzed using WES, 174 (45%) using WGS, and 11 (3%) using TSO500. As of May 2023, of the 343 sequenced pts that have progressed after standard therapy, 14 patients (4%) have been treated with molecularly matched TTs. The actionable targets were TMB-high ( >10mut/MB) (n = 4), FGFR-mutations/-fusions (n = 4), BRAFv600E (n = 2), NTRK-fusions (n = 2), PDGFRA-fusion (n = 1) and MET-mutation (n = 1). Additionally, germline mutations were reported in 8 patients (2%). CONCLUSION: Genomic profiling revealed actionable targets and new therapeutic options for glioblastoma pts. A full and updated overview of patient characteristics, actionable targets and survival data will be presented at the meeting.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1046
Abstract 1046: Tracking tumor mutations in ctDNA through repetitive plasma samples in patients with newly diagnosed brain cancer
Introduction: Glioblastoma (GBM) is an aggressive brain cancer with a median overall survival of 16-24 months. Evaluation of treatment effect can be difficult as pseudo progression is seen in approximately 15% of patients. Hence, effective treatment can be stopped prematurely and no approved or standard second line treatment exist. Genomic alterations during treatment can cause treatment resistance and treatment failure. In order to investigate the genomic alterations, consecutive tissue samples are wanted. However, this is often not possible due to risk doing surgery. Therefore, liquid biopsies from plasma, containing circulating cell-free DNA (cfDNA) and circulating cell-free tumor DNA (ctDNA) might be an alternative. Based on findings by our group, we aim to improve treatment evaluation and suggest targeted treatment possibilities by investigating the role of cfDNA and ctDNA in a large prospective cohort, included from a neurooncological out-patient clinic. Materials and Methods: Newly diagnosed patients with GBM, a performance status of 0-1 and planned for concurrent chemo/radiation will be eligible. Whole genome sequencing (WGS) will be done on tissue. Peripheral blood will be collected in cell stabilizing Blood Collection Tubes (STRECK) and cfDNA quantified on a Qubit Fluorometer. Samples will be collected before the concurrent treatment and at fixed time points until progression with a total of 8-10 samples per patient. For the ctDNA analyses, a patient specific tumor mutation will be selected based upon WGS from tumor tissue. The identified mutation will be quantified in plasma (ctDNA) by droplet digital PCR (ddPCR). Dual labeled fluorescent probes for the mutation and the wild type loci will be used and PCR reaction mixtures will be run. Mutant allele fractions (AFs) ≥0.001 (0.1%) will be detected. An increase in ctDNA AF will be recorded if the AF increases from non-detectable to detectable levels (AF ≥ 0.001) or increases in two consecutive samples. Results: Inclusion began in June 2022 and by time of abstract deadline, we have 27 patients included. Of these, 16 have completed the concurrent setting with a total of five samples per patient. One patient has died and two have progressed. Hence, 24 patients are still on-treatment and sampling and accrual will continue. The first analyses for cfDNA will be run in the winter of 2022/2023 and results will be presented at the conference. CtDNA analyses are planned for autumn 2023. Expected Impact: The expected impacts of this study are specifically in two clinical areas: treatment evaluation and development of new treatment strategies. We aim to 1) find correlation between cfDNA/ctDNA and the clinical course2) detect a relapse earlier than imaging with MRI and FET/PET analyses3) aid to diagnose pseudo progression4) use ctDNA for detection of clonal selection5) test concordance between mutations detected in tissue and in plasma Citation Format: Dorte Schou Nørøxe, Lise Barlebo Ahlborn, Vincent Fougner, Thomas Urup, Benedikte Hasselbalch, Christina Westmose Yde, Hans Skovgaard Poulsen, Ulrik Lassen. Tracking tumor mutations in ctDNA through repetitive plasma samples in patients with newly diagnosed brain cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1046.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1046
Abstract 1046: Tracking tumor mutations in ctDNA through repetitive plasma samples in patients with newly diagnosed brain cancer
Introduction: Glioblastoma (GBM) is an aggressive brain cancer with a median overall survival of 16-24 months. Evaluation of treatment effect can be difficult as pseudo progression is seen in approximately 15% of patients. Hence, effective treatment can be stopped prematurely and no approved or standard second line treatment exist. Genomic alterations during treatment can cause treatment resistance and treatment failure. In order to investigate the genomic alterations, consecutive tissue samples are wanted. However, this is often not possible due to risk doing surgery. Therefore, liquid biopsies from plasma, containing circulating cell-free DNA (cfDNA) and circulating cell-free tumor DNA (ctDNA) might be an alternative. Based on findings by our group, we aim to improve treatment evaluation and suggest targeted treatment possibilities by investigating the role of cfDNA and ctDNA in a large prospective cohort, included from a neurooncological out-patient clinic. Materials and Methods: Newly diagnosed patients with GBM, a performance status of 0-1 and planned for concurrent chemo/radiation will be eligible. Whole genome sequencing (WGS) will be done on tissue. Peripheral blood will be collected in cell stabilizing Blood Collection Tubes (STRECK) and cfDNA quantified on a Qubit Fluorometer. Samples will be collected before the concurrent treatment and at fixed time points until progression with a total of 8-10 samples per patient. For the ctDNA analyses, a patient specific tumor mutation will be selected based upon WGS from tumor tissue. The identified mutation will be quantified in plasma (ctDNA) by droplet digital PCR (ddPCR). Dual labeled fluorescent probes for the mutation and the wild type loci will be used and PCR reaction mixtures will be run. Mutant allele fractions (AFs) ≥0.001 (0.1%) will be detected. An increase in ctDNA AF will be recorded if the AF increases from non-detectable to detectable levels (AF ≥ 0.001) or increases in two consecutive samples. Results: Inclusion began in June 2022 and by time of abstract deadline, we have 27 patients included. Of these, 16 have completed the concurrent setting with a total of five samples per patient. One patient has died and two have progressed. Hence, 24 patients are still on-treatment and sampling and accrual will continue. The first analyses for cfDNA will be run in the winter of 2022/2023 and results will be presented at the conference. CtDNA analyses are planned for autumn 2023. Expected Impact: The expected impacts of this study are specifically in two clinical areas: treatment evaluation and development of new treatment strategies. We aim to 1) find correlation between cfDNA/ctDNA and the clinical course2) detect a relapse earlier than imaging with MRI and FET/PET analyses3) aid to diagnose pseudo progression4) use ctDNA for detection of clonal selection5) test concordance between mutations detected in tissue and in plasma Citation Format: Dorte Schou Nørøxe, Lise Barlebo Ahlborn, Vincent Fougner, Thomas Urup, Benedikte Hasselbalch, Christina Westmose Yde, Hans Skovgaard Poulsen, Ulrik Lassen. Tracking tumor mutations in ctDNA through repetitive plasma samples in patients with newly diagnosed brain cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1046.
- Open Access
- 28 September 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac157
Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation
The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.
- 28 September 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac157
Open AccessImplementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation
The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.